AREDIA Drug Patent Profile

When do Aredia patents expire, and what generic alternatives are available?

Aredia is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in AREDIA is pamidronate disodium. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the pamidronate disodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Aredia

A generic version of AREDIA was approved as pamidronate disodium by HIKMA on April 30^th, 2001.

Summary for AREDIA

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	68
Clinical Trials:	12
Patent Applications:	4,777
DailyMed Link:	AREDIA at DailyMed

Recent Clinical Trials for AREDIA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Ottawa Hospital Research Institute	Phase 4
Masonic Cancer Center, University of Minnesota	Phase 2
Amgen	Phase 4

See all AREDIA clinical trials

US Patents and Regulatory Information for AREDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-001	Oct 31, 1991		DISCN	Yes	No
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-003	May 6, 1993		DISCN	No	No
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-004	May 6, 1993		DISCN	No	No

Expired US Patents for AREDIA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-001	Oct 31, 1991
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-004	May 6, 1993
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-004	May 6, 1993
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-001	Oct 31, 1991
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-003	May 6, 1993
Novartis	AREDIA	pamidronate disodium	INJECTABLE;INJECTION	020036-003	May 6, 1993

International Patents for AREDIA

See the table below for patents covering AREDIA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	591066
Netherlands	7414947
Norway	853087
Israel	75990	STABLE CRYSTAL MODIFICATION OF DISODIUM 3-AMINO-1-HYDROXYPROPANE-1,1-DIPHOSPHONATE,PROCESS FOR ITS MANUFACTURE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
Hungary	T38361
United Kingdom	1435885
Portugal	80916	PROCESSO PARA A PREPARACAO DE UMA NOVA MODIFICACAO DE CRISTAIS

Market Dynamics and Financial Trajectory for AREDIA

Last updated: March 25, 2026

What Is the Current Market Position of AREDIA?

AREDIA (pamidronate disodium) is a prescription bisphosphonate primarily used to prevent skeletal fractures in patients with multiple myeloma and bone metastases from breast cancer. Since its approval in 1997 by the FDA, it has experienced a steady decline in market share amid increased competition, patent expirations, and evolving treatment guidelines.

Sales Data Overview (2020–2022)

Year	Global Sales (USD million)	Market Share in Bisphosphonates	Key Markets (USD million)
2020	250	15%	US: 125; Europe: 70; Rest of World: 55
2021	210	12%	US: 90; Europe: 65; Rest of World: 55
2022	180	9%	US: 74; Europe: 55; Rest of World: 51

Note: Sales are declining due to competition from denosumab (Xgeva, Prolia) and introduction of newer therapies.

---

What Factors Are Influencing Market Dynamics?

Patent and Exclusivity Status

• The last patent for AREDIA expired in 2011 in the US and 2012 in Europe.
• Lack of patent protection has led to generic versions entering markets, pressuring pricing and sales.

Competition

• Denosumab (Xgeva, Prolia) by Amgen has gained dominance in indications for skeletal-related events.
• Biopharmaceuticals like zoledronic acid (Reclast) compete on efficacy, safety profile, and dosing convenience.

Regulatory Environment

• The FDA and EMA have issued guidance favoring denosumab due to its dosing frequency and safety profile.
• Certain jurisdictions have approved biosimilars of denosumab, further reducing AREDIA's market share.

Clinical Adoption Trends

• Shift from bisphosphonates to RANKL inhibitors such as denosumab in oncology and osteoporosis indications.
• Updated guidelines from ASCO and NCCN favor denosumab over bisphosphonates for several indications.

---

What Is the Financial Trajectory Outlook for AREDIA?

Revenue Projections

• Revenue decline expected to continue at a CAGR of approximately -10% over the next five years.
• Estimated global sales in 2023: USD 150 million, decreasing to USD 100–120 million by 2028.

Market Drivers

• Increased use of denosumab and biosimilar alternatives.
• Declining prescription volume due to safety concerns such as osteonecrosis of the jaw.

Key Challenges

• Limited pipeline developments for AREDIA.
• Limited commercial incentives for new indications or formulations.
• Price erosion due to generics and biosimilars.

Strategic Actions

• Potential repositioning or combination therapies with newer agents.
• Focus on niche indications where bisphosphonates retain an advantage.
• Licensing or partnership opportunities to extend lifecycle.

How Have Regulatory and Market Factors Affected Sales?

Factor	Impact
Patent expirations	Entry of generics reduces pricing and market share
Competition from denosumab	Market shift favoring monoclonal antibodies
Safety profile concerns	Reduced prescription rates due to adverse events
Market consolidation	Fewer players mean less diversification in therapy options

What Are the Future Opportunities or Risks?

Opportunities

• Development of fixed-dose combinations.
• Expansion into specialty niches or emerging markets.
• Partnerships with biosimilar producers to renew licensing deals.

Risks

• Accelerated market share erosion owing to biosimilar entry.
• Regulatory restrictions due to safety issues.
• Pricing pressures from global healthcare initiatives.

---

Key Takeaways

• AREDIA's market has contracted significantly since patent expiry, with sales declining at roughly 10% annually.
• Competition from denosumab and biosimilars remains the primary challenge.
• Limited pipeline and innovation reduce its potential for growth.
• Future strategies depend on niche market exploitation and potential alliances.

---

FAQs

Q1: Will AREDIA regain market share?
No. The shift toward denosumab and biosimilars, along with safety concerns and declining prescribing habits, makes a market share increase unlikely.

Q2: Are there any approved new indications for AREDIA?
As of 2023, no new indications have been approved for AREDIA.

Q3: How does the safety profile of AREDIA compare to competitors?
AREDIA has a comparable safety profile but is associated with higher risks of osteonecrosis of the jaw and renal toxicity compared to denosumab.

Q4: What is the outlook for biosimilar competition?
Biosimilars of denosumab are approved and entering key markets, accelerating price competition and reducing AREDIA's viability.

Q5: Can repositioning strategies revive AREDIA's market?
Potentially, but success depends on identifying unique niches and securing new partnerships. The current trend favors newer agents over bisphosphonates.

---

References

[1] U.S. Food and Drug Administration. (1997). FDA approves pamidronate for multiple myeloma.
[2] MarketWatch. (2022). Bisphosphonates Market by Type and Region - Global Forecast to 2028.
[3] NCCN Clinical Practice Guidelines in Oncology. (2022). Bone Health in Cancer Patients.
[4] European Medicines Agency. (2012). Regulatory status of biosimilars.
[5] Xie, H., et al. (2021). Safety of bisphosphonates versus denosumab: A meta-analysis. Bone, 144, 115838.